In a letter to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) expressed concerns regarding two provisions in the 2021 Affordable Care Act (ACA) Notice of Benefit and Payment Parameters proposed rule. This proposal, if implemented, would update the regulatory and financial standards applied to ACA Exchanges.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The American Society of Clinical Oncology (ASCO) today released a position statement on state drug repository programs, outlining ASCO’s support for drug repository programs solely for oral medications provided they are maintained within a closed system. The Society also makes recommendations to help ensure that these programs are implemented appropriately, with sufficient patient protections in place.
The meetings focused on drug pricing, access to clinical trials, Medicaid expansion and block grants, accelerated drug approval pathways, and other issues affecting people with cancer and their oncology care teams.
On February 18, 106 organizations representing patients, providers, medical researchers, survivors, and families joined together to urge Congress to include the bipartisan CLINICAL TREATMENT Act (H.R. 913) in the upcoming ‘must pass’ healthcare extenders package, which is expected to pass this spring.
On January 30, Jerome Seid, MD, FACP, testified during a hearing of the Michigan State Senate Committee on Health Policy and Human Services in support of SB 612, a bill that would make important reforms to prior authorization and step therapy protocols. Dr. Seid is a member of the Association for Clinical Oncology (ASCO) and past president of the Michigan Society of Hematology and Oncology (MSHO).
As a practicing hematologist and oncologist in Warren, Michigan, Dr. Seid provided first-hand experience to the Committee on how prior authorization impacts his patients.
Price transparency is often highlighted in conversations about health care reform in the U.S. since prices vary for health care goods and services by location, provider choice, health insurance benefit design, and other factors. Such complexity within the health care delivery system makes it difficult to distill and share information that would be meaningful and useful to patients and providers.
ASCO recently submitted comments to the House Committee on Ways and Means and the House Rural and Underserved Communities Health Task Force in response to a request for information (RFI) on priority topics that affect the health status and outcomes for rural and underserved communities.